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Diversity of Cystic Fibrosis Mutation-Screening
Practices
To the Editor:
As the most common lethal recessive disorder in North
America, cystic fibrosis (CF) has been discussed as a
potential target of nationwide carrier screening ever
since the cloning of the causative CFTR gene in 1989
(Kerem et al. 1989). Practical implementation of such
proposals has been impeded, however, by the extreme
mutational heterogeneity of CFTR alleles within the car-
rier population, with upwards of 600 different muta-
tions identified thus far (Zielenski and Tsui 1995). Aside
from the most prevalent mutation, DF508, most of these
alleles are extremely rare or even “private,” although
approximately half a dozen account for 1%–3% each
of carriers in the general Caucasian population, and
other subsets are relatively more common in other ethnic
groups. Therefore, analysis of numerous mutations is
required to reach satisfactory carrier detection levels.
Studies in the general Caucasian population have re-
vealed that at least 15–20 mutations must be tested to
detect 180% of obligate carriers (Cystic Fibrosis Genetic
Analysis Consortium 1994). An exception is the Ash-
kenazi Jewish community, in which the analysis of only
seven mutations can detect ∼97% of carriers, making
high-sensitivity carrier screening more readily attainable
(Eng et al. 1997). The range of mutations tested has
steadily increased over the years, but there are still no
authoritative national guidelines specifying a minimum
number of CF mutations acceptable in a population
screening panel (i.e., screening for unknown mutations
in individuals with no family history and thus no index
case with a known mutation). In the early months
shortly after the cloning of the CFTR gene, screening
for four to seven of the most common mutations was
the norm, but as the total number of cataloged CFTR
mutations has expanded, and additional ethnic-specific
mutations have been identified, the size of available test
panels also has increased.
The only way (theoretically) to detect all possible mu-
tations would be to sequence the entire gene, but the
cost of that approach would be prohibitive for popu-
lation screening. Therefore, laboratories developing
CFTR mutation tests have had to be creative in their
choice of technique and their selection of appropriate
mutation panels. Techniques used have included PCR
amplification with electrophoresis and/or restriction en-
donuclease digestion of the products, dot blot hybridi-
zation with allele-specific oligonucleotide (ASO) probes,
reverse dot blots, pooled ASO and probe-elution strat-
egies, conformational analysis, and (still under devel-
opment) various types of oligonucleotide microarrays
(DeMarchi et al. 1994; Ravnik-Glavac et al. 1994; Wall
et al. 1995; Shuber et al. 1997;). In the absence of guide-
lines, the choice of number and type of mutations in CF
test panels has been left to the discretion of the individual
laboratories.
Like the mutations themselves, the number of labo-
ratories offering such testing has been increasing over
the years, yet there has been no systematic survey of the
range of CF mutations being tested across the country.
For several years, the American College of Medical Ge-
netics/College of American Pathologists (ACMG/CAP)
Biochemical and Molecular Genetics Resource Com-
mittee has been administering a molecular genetics pro-
ficiency testing program for CF and other disorders, pro-
viding a means to collect such data. The 45 laboratories
currently participating in the CF challenges represent
most of those offering such testing in the United States.
As part of our March 1997 proficiency challenge, we
included a survey questionnaire to ascertain the range
of mutations tested by the laboratories offering cystic
fibrosis mutation screening. Forty-three (96%) of the 45
participating laboratories subscribing to the CF chal-
lenge responded to this survey. Of those, there was a
wide range in the number of mutations tested, from just
1 to 70. One laboratory offers testing for DF508 only,
and one or two laboratories each offer testing for 5, 7,
Letters to the Editor 1253
Figure 1 Number of CFTR mutations screened by participating laboratories.
8, 9, 11, 16, 17, 18, 22, 24, 26, 30, 31, 32, 34, or 70
mutations, with the median number centering around
12–14 mutations (fig. 1).
Aside from the absolute number of mutations, other
notable findings in some of the laboratories’ screening
panels emerged from this survey. For example, 13 of the
laboratories do not test for R117H, which many would
feel is one of the relatively more common and important
mutations, associated with both classical CF and con-
genital bilateral absence of the vas deferens (Jezequel et
al. 1995). And only two of the other laboratories spe-
cifically indicated that they include testing for the in-
tronic 5/7/9T polymorphism that markedly affects phe-
notypic expression of R117H and some other CFTR
mutations (Kiesewetter et al. 1993; Chillon et al. 1995).
Three laboratories do not include the prevalentW1282X
Ashkenazi Jewish mutation, which would seem essential
for any test panel directed at a North American urban
population. Some of the laboratories included written
comments that their panels cannot distinguish between
mutations DF508 and DI507 (both 3-nucleotide dele-
tions of adjacent codons) or G551D and R553X (two
of the more common point mutations), which our
ACMG/CAP committee already suspected, based on the
results of our earlier CF challenges.
It is important to note that our survey addressed nei-
ther which laboratories are using their panels for testing
of known mutations in at-risk relatives, as opposed to
random proband or population screening, nor which
particular ethnic groups, if any, are being targeted. These
more limited and predefined applications would allow
for more narrow test panels. In the same vein, it is pos-
sible that some of the laboratories in our survey perform
CF mutation analysis primarily for research purposes.
(The confidential structure of the CAP survey program
precludes identification or contact of the individual lab-
oratories by the resource committee.) Finally, although
we believe this survey to be fairly comprehensive, there
are undoubtedly some additional academic and/or com-
mercial laboratories involved in CF testing that did not
participate or respond.
In April 1997, the NIH convened a Consensus Con-
ference on Cystic Fibrosis Testing. The consensus panel
recommended that population-based CF screening be of-
fered to all pregnant couples and those contemplating
pregnancy in a program to be phased in over time (NIH
Consensus Statement 1997). Without specifying a pre-
cise number of mutations, they stated that any test panel
used should be capable of detecting x90%of Caucasian
carriers while achieving the best available sensitivity in
other ethnic groups. For certain homogeneous ethnic
groups, as few as five mutations would be sufficient to
meet this criterion. But for general population screening
in a country as heterogeneous as the United States, it is
clear that many more mutations will need to be included.
In the absence of commercial test kits, setting up in-
house multiplex testing for large numbers of CFTR mu-
tations has proven to be a challenging and expensive
exercise for most routine diagnostic molecular genetics
laboratories, especially for those whose test volume does
not lend itself to large-scale automation of the PCR and
hybridization steps. A number of these laboratories have
already abandoned CF mutation screening and refer
their cases out to large reference laboratories that test
as many as 70 or more mutations. The NIH panel’s
recommendation should exert even more pressure in this
direction, although it might also inspire manufacturers
to develop marketable CFTR mutation test kits. While
most of the mutations beyond the first 10 or 20 are
extremely rare, it could be argued that screening for
fewer than 10–20 does not represent the current stan-
dard of care, unless the laboratory is restricting its testing
to particular well-characterized ethnic groups such as
Ashkenazi Jews. In any case, our experience suggests that
more explicit guidelines specifying particular mutations
and minimal test panel sensitivities for each ethnic pop-
ulation being screened would be prudent and helpful.
Such guidelines could be recommended by professional
practice organizations like the ACMG and CAP or
through the NIH consensus conference process. In the
meantime, this survey by the ACMG/CAP Biochemical
and Molecular Genetics Resource Committee provides
a valuable snapshot of the state and extent of CF mu-
tation testing in the country at present and one that the
broader medical genetics community should consider as
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it ponders how best to extend these services to larger
populations.
Acknowledgments
The authors thank the other members of the ACMG/CAP
Biochemical and Molecular Genetics Resource Committee, Jill
Kachin and other members of the CAP support staff, and all
the participating laboratories in the CF proficiency testing pro-
gram for assistance in the accrual and tabulation of these data.
WAYNE W. GRODY,1 ROBERT J. DESNICK,2
NANCY J. CARPENTER,3 AND WALTER W. NOLL4
1UCLA School of Medicine, Los Angeles; 2Mount Sinai
School of Medicine, New York; 3Chapman Institute of
Medical Genetics, Tulsa; and 4Dartmouth-Hitchcock
Medical Center, Lebanon, NH
References
Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S,
Romey M-C, et al (1995) Mutations in the cystic fibrosis
gene in patients with congenital absence of the vas deferens.
N Engl J Med 332:1475–1480
Cystic Fibrosis Genetic Analysis Consortium (1994) Popula-
tion variation of common cystic fibrosis mutations. Hum
Mutat 4:167–177
DeMarchi JM, Beaudet AL, Caskey CT, Richards CS (1994)
Experience of an academic reference laboratory using au-
tomation for analysis of cystic fibrosis mutations. Arch
Pathol Lab Med 118:26–32
Eng CM, Schechter C, Robinowitz J, Fulop G, Burgert T, Levy
B, Zinberg R, et al (1997) Prenatal genetic carrier testing
using triple disease screening. JAMA 278:1268–1272
Jezequel P, Dorval I, Fergelot P, Chauvel B, Le Treut A, Le
Gall JY, Le Lannou D, et al (1995) Structural analysis of
CFTR gene in congenital bilateral absence of vas deferens.
Clin Chem 41:833–835
Kerem B-S, Rommens JM, Buchanan JA, Markiewicz D, Cox
TK, Chakravarti A, Buchwald M, et al (1989) Identification
of the cystic fibrosis gene: genetic analysis. Science 245:
1073–1080
Kiesewetter S, Macek M, Davis C, Curristin SM, Chu CS,
Graham C, Shrimpton AE, et al (1993) A mutation in CFTR
produces different phenotypes depending on chromosomal
background. Nat Genet 5:274–278
NIH Consensus Statement Online (1997) Genetic testing for
cystic fibrosis. http://odp.od.nih.gov/consensus/statements/
cdc/106/106stmt.html (April)
Ravnik-Glavac M, Glavac D, Dean M (1994) Sensitivity of
single-strand conformation polymorphism and heterodu-
plex method for mutation detection in the cystic fibrosis
gene. Hum Mol Genet 3:801–807
Shuber AP, Mchalowsky LA, Nass GS, Skotetsky J, Hire LM,
Kotsopoulos SK, Phipps MF, et al (1997) High throughput
parallel analysis of hundreds of patient samples for more
than 100 mutations in multiple disease genes. Hum Mol
Genet 6:337–347
Wall J, Cai S, Chehab FF (1995) A 31-mutation assay for cystic
fibrosis testing in the clinical molecular diagnostics labo-
ratory. Hum Mutat 5:333–338
Zielenski J, Tsui L-C (1995) Cystic fibrosis: genotypic and
phenotypic variations. Annu Rev Genet 29:777–807
Address for correspondence and reprints: Dr. Wayne W. Grody, UCLA School
of Medicine, Medical Genetics/Molecular Pathology, 10833 Le Conte Avenue,
Los Angeles, CA 90095-1732.
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6205-0031$02.00
Am. J. Hum. Genet. 62:1254–1258, 1998
Linkage Disequilibrium Analysis in a Recently
Founded Population: Evaluation of the Variegate
Porphyria Founder in South African Afrikaners
To the Editor:
Variegate porphyria (VP; MIM 176200) is relatively rare
in most populations, but it is one of the most common
autosomal dominant genetic disorders in South Africa
(Dean 1971). The disease is characterized by a diversity
of symptoms, including a variable picture of skin symp-
toms and acute attacks. By means of genealogical stud-
ies, the history of VP in South Africa can be traced back
to the marriage of a Dutch couple in the Cape of Good
Hope in 1688 (Dean 1971). This, along with the high
prevalence of VP in South Africa, has promoted the
founder-gene hypothesis for VP in this country.
Mutations in the protoporphyrinogen oxidase gene
(PPOX), the seventh enzyme in the heme biosynthetic
pathway, have been shown to be causative of VP (Dey-
bach et al. 1996; Meissner et al. 1996; Warnich et al.
1996b; Lam et al. 1997). This gene has been mapped
to chromosome 1q22 by FISH (Taketani et al. 1995),
and the position has been confirmed by linkage analysis
(Roberts et al. 1995). Three mutations have been de-
scribed in South African VP patients, but one of these,
a CrT transition at nucleotide position 452 (R59W),
was found in ∼90% of patients (Meissner et al. 1996;
Warnich et al. 1996b). This mutation spanned a CpG
dinucleotide, and, to exclude the possibility of a recur-
rent mutation, intragenic haplotype studies were under-
taken. Mutation R59Wwas shown to be associatedwith
one of four potential haplotypes defined by two diallelic
polymorphisms in exon 1 (Warnich et al. 1996b), thus
supporting the founder hypothesis. However, this was
not totally conclusive evidence, since the alleles associ-
ated with the R59W mutation are also the common al-
leles in the normal population for each of the polymor-
phisms (L. Warnich, unpublished data).
If the high incidence of a genetic disease in a particular
population is due to a founder effect, most cases studied
